Continuation of Milnacipran Therapy During Pregnancy in a Patient with Severe PTSD and Psychotic Depression: A Case Study with Three-Year Pediatric Outcomes - Scorecard - MDSpire

Continuation of Milnacipran Therapy During Pregnancy in a Patient with Severe PTSD and Psychotic Depression: A Case Study with Three-Year Pediatric Outcomes

  • By

  • Maximilian Preiss

  • Lucie Bartova

  • April 27, 2026

  • 0 min

Share

Clinical Scorecard: Continuation of Milnacipran Therapy During Pregnancy in a Patient with Severe PTSD and Psychotic Depression: A Case Study with Three-Year Pediatric Outcomes

At a Glance

CategoryDetail
Condition
Key MechanismsMilnacipran is a serotonin-norepinephrine reuptake inhibitor, affecting both serotonin and norepinephrine levels.
Target Population
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • I
      • n
      • c
      • l
      • u
      • d
      • e
      • s
      • p
      • e
      • c
      • i
      • f
      • i
      • c
      • s
      • c
      • r
      • e
      • e
      • n
      • i
      • n
      • g
      • t
      • o
      • o
      • l
      • s
      • f
      • o
      • r
      • s
      • u
      • i
      • c
      • i
      • d
      • a
      • l
      • i
      • t
      • y
      • a
      • n
      • d
      • d
      • e
      • p
      • r
      • e
      • s
      • s
      • i
      • v
      • e
      • s
      • y
      • m
      • p
      • t
      • o
      • m
      • s
      • .

      Risks

        Patient & Prescribing Data

        Clinical Best Practices

        • additional_recommendation

        References

        Original Source(s)

        Continuation of Milnacipran Therapy During Pregnancy in a Patient with Severe PTSD and Psychotic Depression: A Case Study with Three-Year Pediatric Outcomes

        • by Maximilian Preiss, Lucie Bartova

        • April 27, 2026

        Related Content

        Assessing the Use of Wearable Mobile-Monitoring Devices Among Individuals With Serious Mental Illness: Qualitative Acceptability and Feasibility Study

        Gender-Diverse Youths Reported More Psychotic-Like Experiences

        Longitudinal cohort data linked bullying and persistently unsupportive state gender-identity policies with worsening psychotic-like experiences among gender-diverse youths.

        FDA Approves Auvelity for Agitation in Alzheimer’s Disease

        The oral combination therapy expands treatment options for agitation associated with dementia due to Alzheimer’s disease.